Douglas G. Gray

Partner

Providence

douglas.gray@troutman.com

D 401.276.6673



Douglas guides individual investors, management teams, corporate buyers and sellers, venture capitalists, and private equity firms through major corporate transactions.

OVERVIEW

Douglas brings a broad range of experience in mergers and acquisitions, corporate governance, strategic alliances, and commercial ventures. He represents medical device, pharmaceutical, and health care-related companies and products.

Douglas has an active collaborations practice, negotiating licensing, joint venture, and development agreements related to intellectual property rights.

REPRESENTATIVE MATTERS

- Represented Imugene Ltd. (IMU:AUX), a clinical stage immuno-oncology company developing a range of new and novel immunotherapies seeking to activate the immune system of cancer patients to treat and eradicate tumors, in its strategic transaction with Precision BioSciences, Inc., valued up to $227 million.
- Advised Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) in the sale of its migraine business, including NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults, and zavegepant to Pfizer in a total deal consideration valued at approximately $13 billion.
- Represented Oscor, Inc., a leading designer, developer, and manufacturer of highly specialized implantable cardiac pacing leads, venous access systems, and diagnostic catheters, in its sale of $220 million to Integer Holdings Corporation.
- Represented Shanghai Haohai Biological Technology Co., Ltd., a public company traded on the Hong Kong and Shanghai stock exchanges, in connection with its $40 million series A preferred equity investment in Eirion Therapeutics, Inc., a biotech startup based in Massachusetts, and related licensing arrangements.
- Advised Biohaven Pharmaceutical Holding Company (NYSE: BHVN) in its acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc., which it did not previously own, and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab.
- Advised Biohaven Pharmaceutical Holding Company (NYSE: BHVN) and its affiliate BioShin Limited in a $60 million series A preferred equity financing of BioShin Limited, Biohaven’s subsidiary.

©2026 Troutman Pepper Locke

- Represented Leonard Valve Company, a Rhode Island-based designer and manufacturer of water temperature control valves and monitoring devices used in institutional and commercial applications, and its owners in the sale of the equity interests of Leonard Valve to Bessemer Investors.

AWARDS

- *The Best Lawyers in America*®, Providence Corporate Law Lawyer of the Year (2015, 2023, 2027)
- *The Best Lawyers in America*®, Providence Mergers and Acquisitions Law Lawyer of the Year (2026)
- *The Best Lawyers in America*®, Corporate Law, Mergers and Acquisitions Law (2010-2027)
- *Rhode Island Monthly Professional,* Excellence in the Law, Business Law (2023-2024)
- *Chambers USA*: Corporate/Commercial, Rhode Island (2007-2026)
- *Super Lawyers*® Rhode Island, Mergers & Acquisitions (2011-2020)
- AV Rating® by Martindale-Hubbell

TOP AREAS OF FOCUS

- Corporate Governance
- Emerging Companies + Venture Capital
- Health Care + Life Sciences
- Insurance + Reinsurance
- Technology

ALL AREAS OF FOCUS

- Capital Markets
- Corporate
- Corporate Governance
- Emerging Companies + Venture Capital
- Health Care + Life Sciences
- Insurance + Reinsurance
- Life Sciences Transactions
- Mergers + Acquisitions
- Private Equity
- Technology

PROFESSIONAL/COMMUNITY INVOLVEMENT

- Unauthorized Practice of Law Committee, Supreme Court of the State of Rhode Island
- Member, Rhode Island Bar Association; Business Organization Committee; Ethics and Professionalism Committee
- State liaison, American Bar Association, Corporate Laws Committee
- Firm representative, Lab Central, Cambridge, MA
- Firm representative, New England Medical Innovation Center (NEMIC)
- Trustee, French American School of Rhode Island (2015-Present)
- Director and advisor, The UCAP School and Fund for UCAP (1999-Present)

- Director, Blithewold Arboretum (2008-2018), chair; vice chair
- Director, Community Prep School (2010-2018)
- Trustee, The Haitian Project (2010-Present); director (1995-2010); chair; vice chair
- Director, Habitat for Humanity East Bay (1996-2006)
- Director, Newport Film (2008-2015)

EDUCATION AND CERTIFICATIONS

EDUCATION

- Notre Dame Law School, J.D., 1993, executive articles editor, *Journal of Legislation*
- Yale University, B.A., 1988

BAR ADMISSIONS

- Rhode Island

COURT ADMISSIONS

- U.S. District Court, District of Rhode Island

SPEAKING ENGAGEMENTS

- Speaker, "Innovate Newport: Health Tech Industry Spotlight Series," The New England Medical Innovation Center, May 29, 2025.

PUBLICATIONS

- Co-author, "How Clinical Integration Is Impacting Deal Terms for AI-Enabled Medical Devices," *Reuters*, November 11, 2026.
- Co-author, "Distribution Agreement Call Options May Provide Life Sciences Acquirers with an Asset Preview," *Reuters Legal News*, June 30, 2026.
- Co-author, "Pipeline Gaps Create M&A Opportunities for Deal-Ready Life Sciences Companies," *Reuters Legal News*, March 30, 2026.
- Co-author, "Life Sciences Companies May Turn to Spin-Offs to Avoid Sell-Offs," *Reuters Legal News*, October 9, 2025.
- Co-author, "Biotech Collaborations Can Ease Uncertainty Amid FDA Shift," *Law360*, July 17, 2025.
- Co-author, "Embattled Biotechs Facing Uncertainty at the FDA Look to Collaborative Deal Structures," *Troutman Pepper Locke*, May 20, 2025.

MEDIA COMMENTARY

- Quoted, "The Buyers' Wishlist: What Makes a Life Sciences Deal Stack Up?" *Life Sciences IP Review*, August 25, 2026.
- Quoted, "Where Big Pharma Is Betting Big in the M&A Boom," *Life Sciences IP Review*, July 29, 2026.
- Quoted, "Buying the Brains: Why Is Big Pharma Shopping for Innovation?," *Life Sciences IP Review*, July 27, 2026.